{"id":77851,"date":"2026-02-26T12:05:44","date_gmt":"2026-02-26T12:05:44","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/"},"modified":"2026-02-26T12:05:44","modified_gmt":"2026-02-26T12:05:44","slug":"amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/","title":{"rendered":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt;\">Presentation showcases how Amphista\u2019s Eclipsys<b>\u00ae<\/b> platform is enabling the development of Targeted Glue&#x2122; degraders, which recruit diverse E3 ligases, describing for the first time the degradation of KRAS G12D by the functional recruitment of DCAF11<\/li>\n<li style=\"margin-bottom:8pt;\">Amphista\u2019s proprietary target-centric approach enables the development of Targeted Glues&#x2122; with exceptional profiles with its first clinical candidate, AMX-883, a DCAF16-dependent Targeted Glue&#x2122; degrader of BRD9, set to enter the clinic in H2 2026 for the treatment of AML<\/li>\n<li style=\"margin-bottom:8pt;\">Amphista has successfully developed its Targeted Glues&#x2122; into degrader-antibody-conjugates (DACs), demonstrating the versatility of its platform beyond traditional small molecule approaches\n<p><\/li>\n<\/ul>\n<p align=\"justify\"><b>Cambridge, UK, 26 February 2026 <\/b>\u2013 Amphista Therapeutics (\u201cthe Company\u201d or \u201cAmphista\u201d), a leader in the discovery and development of next generation non-cereblon\/VHL targeted protein degradation (TPD) medicines, presented new data at the Keystone Symposia on Proximity Based Biology and Therapeutics: Targeted Protein Degradation and Beyond in Banff, AB, Canada, 23-26 February.<\/p>\n<p align=\"justify\">In an oral presentation titled \u201c<i>Expanding Targeted Glue<\/i>&#x2122;<i> Applications for Clinical Use by Recruiting Novel E3 Ligases<\/i>\u201d, Louise Modis, Chief Scientific Officer at Amphista, outlined the translation of Amphista\u2019s Targeted Glue&#x2122; technology from discovery to clinical development. It showcased how the Company\u2019s target-first approach and proprietary chemistry is delivering differentiated and advanced molecular glue degraders beyond traditional cereblon\/VHL-based approaches.<\/p>\n<p align=\"justify\">The presentation built on insights shared at the TPD &amp; Induced Proximity Summit in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vy_7qBgC-tQ2TEw4bt6RWNdItYdeG9X3Zv8dnh7IUsQ1oEmJTuUK4idSGm-yGfWrWKygOvNynKnajbnTXNXkadKr7ZRWGrbEY9TO1LaN6tNxmenaK-jl688XAlNHOH2WIbvrWXQMB-8iDZ8GuB5ih399TrJUC4yqmaCcuvHGQGTXBRxUmHNlus5RtGQgaDOJpdz9JZtX8qMVszpZX7yd64MnlVe7_MKAkpKaISy_T1bl2VthcHf1-xsr3LZPsKkojma9zcA-6YcSMlzkt3z6J10H7pSzZyIAc6M83EWtzdihIy9n_Ul6C5syNn9vXIjR\" rel=\"nofollow\" target=\"_blank\" title=\"October 2025\">October 2025<\/a>, demonstrated how Amphista is leading the rational discovery and development of molecular glue degraders functioning via novel E3 ligases, including DCAF16, FBXO22 and DCAF11 into clinically viable oral therapeutics.<\/p>\n<p align=\"justify\">Louise provided new data from Amphista\u2019s Targeted Glue&#x2122; pipeline, which exemplifies the exquisite selectivity, deep and sustained target degradation, and exceptional degradation kinetics that can be achieved <i>in vivo<\/i> with this innovative approach. Amphista\u2019s progress is underpinned by its proprietary Eclipsys\u00ae platform technology which combines high-resolution CryoEM of ternary complexes, geometric deep learning, advanced folding algorithms and cheminformatics to rationalize and enhance molecular glue degrader development. The therapeutic potential of Amphista\u2019s chemistry is further expanded by its compatibility with degrader-antibody conjugate (DAC) approaches.<\/p>\n<p align=\"justify\"><b>Louise Modis, Chief Scientific Officer of Amphista Therapeutics, said:<\/b> \u201cWe have made significant progress in advancing our Targeted Glue&#x2122; technology toward clinical application. This presentation at Keystone demonstrates how Amphista\u2019s mechanistically differentiated approach of recruiting the most structurally efficient E3 ligase &#8211; including DCAF16, FBXO22 and now DCAF11 &#8211; translates into exceptional molecular properties, tissue distribution and degradation of the target. We have now demonstrated that we can successfully and reproducibly harness multiple novel E3 ligases beyond cereblon\/VHL with advanced drug-like degraders. We&#8217;re excited to share data on AMX-883, our first clinical candidate, alongside innovations in degrader-antibody-conjugates and CNS-penetrant degraders that further expands the therapeutic opportunity for our Targeted Glue&#x2122; technology.&#8221;<\/p>\n<p align=\"justify\"><b>Presentation details:\u00a0<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \"><b>Title:<\/b><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \">Expanding Targeted Glue Applications for Clinical Use by Recruiting Novel E3 Ligases<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \"><b>Date and Time:<\/b><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \">Wednesday 25 February 2026, 8:00\u201311:00 AM MST (UTC-7)<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \"><b>Presenter:<\/b><\/td>\n<td style=\"text-align: justify ;  vertical-align: middle; vertical-align: middle ; \">Louise Modis, Chief Scientific Officer, Amphista Therapeutics<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"><b><br \/><\/b><\/p>\n<p align=\"center\"><b>Ends<\/b><\/p>\n<p align=\"justify\"><b>Amphista Therapeutics <\/b><\/p>\n<p align=\"justify\">At Amphista Therapeutics, we are focused on transforming the lives of patients with severe diseases, including cancer and neurodegenerative disorders, through the discovery and development of advanced, next generation targeted protein degradation (TPD) medicines. Amphista applies its proprietary Eclipsys\u00ae platform to generate unique, sequentially bifunctional Targeted Glue&#x2122; therapeutics with a differentiated mechanism and leading drug-like properties. Our portfolio offers the potential to deliver first- and\/or best-in-class therapeutics with performance characteristics beyond the limitations of CRBN and VHL-based agents. Amphista was co-founded by Advent Life Sciences and is additionally funded by a premier group of investors including Forbion, Gilde Healthcare, Novartis Venture Fund, SV\u2019s Dementia Discovery Fund and Eli Lilly. For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3j1sXMr5Kp2XUsSXWfB3pyI75qPVcOcv2Gm2fNATjzeAOL-bVKhpETIlcHaVOa2i0gw-5XI10DJFJITSWBRUdG6DVKb7wPFhbMRkJsueyfo=\" rel=\"nofollow\" target=\"_blank\" title=\"www.amphista.com\">www.amphista.com<\/a><\/p>\n<p align=\"justify\">Amphista, Eclipsys, Targeted Glue, Targeted Glues and the Amphista logo are all trademarks or registered trademarks of Amphista Therapeutics Limited.<\/p>\n<p>For more information please contact:<\/p>\n<p><b>Amphista Therapeutics<\/b><\/p>\n<p>John Goodall<\/p>\n<p>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dY19voV6IR-29DhTuBT-l6X7LSYoxQdtRT4SyHrH3MJ3UVac0Gi9papXgKqFnvXlsmRMFpnukbmI-D1nuqxOBkdI9Ui8FTTZJEFxnG9US4E=\" rel=\"nofollow\" target=\"_blank\" title=\"Info@amphista.com\">Info@amphista.com<\/a><\/p>\n<p><b><br \/><\/b><\/p>\n<p><b>ICR Healthcare<\/b><\/p>\n<p>Namrata Taak, Emily Johnson<\/p>\n<p>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G4Nd0dzl-LHEBUVQ-lmIkDn57h2UEoeAfYLCysdjdNQXElpp4VS7FUXLbwUtJ2QbYGC_aY8121WUVy7pdL7Q_xNT07aa1ok9c-gjQcAW9w1h-g61q91uV6cSlgWM5tQX\" rel=\"nofollow\" target=\"_blank\" title=\"Amphista@icrhealthcare.com\">Amphista@icrhealthcare.com<\/a><\/p>\n<p>Tel: +44 (0)20 3709 5813<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/M2FmMTFkZjUtYjYwYi00OGU5LWFjMDgtNDI4MWEyMWI1YTI1LTcwMDAxNDExNC0yMDI2LTAyLTI2LWVu\/tiny\/Amphista-Therapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presentation showcases how Amphista\u2019s Eclipsys\u00ae platform is enabling the development of Targeted Glue&#x2122; degraders, which recruit diverse E3 ligases, describing for the first time the degradation of KRAS G12D by the functional recruitment of DCAF11 Amphista\u2019s proprietary target-centric approach enables the development of Targeted Glues&#x2122; with exceptional profiles with its first clinical candidate, AMX-883, a [&#8230;]\n","protected":false},"author":1,"featured_media":77852,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic\" \/>\n<meta property=\"og:description\" content=\"Presentation showcases how Amphista\u2019s Eclipsys\u00ae platform is enabling the development of Targeted Glue&#x2122; degraders, which recruit diverse E3 l\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-26T12:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Amphista-Therapeutics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic\",\"datePublished\":\"2026-02-26T12:05:44+00:00\",\"dateModified\":\"2026-02-26T12:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\"},\"wordCount\":685,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\",\"name\":\"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-02-26T12:05:44+00:00\",\"dateModified\":\"2026-02-26T12:05:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/","og_locale":"en_US","og_type":"article","og_title":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic","og_description":"Presentation showcases how Amphista\u2019s Eclipsys\u00ae platform is enabling the development of Targeted Glue&#x2122; degraders, which recruit diverse E3 l","og_url":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-02-26T12:05:44+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/02\/Amphista-Therapeutics.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic","datePublished":"2026-02-26T12:05:44+00:00","dateModified":"2026-02-26T12:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/"},"wordCount":685,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/","url":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/","name":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-02-26T12:05:44+00:00","dateModified":"2026-02-26T12:05:44+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/amphista-therapeutics-presents-new-data-demonstrating-how-its-advanced-eclipsys-platform-is-delivering-targeted-glue-degraders-using-novel-e3-ligases-into-the-clinic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Amphista Therapeutics presents new data demonstrating how its advanced Eclipsys\u00ae platform is delivering Targeted Glue&#x2122; degraders using novel E3 ligases into the clinic"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=77851"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/77851\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/77852"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=77851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=77851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=77851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}